The purpose of this study is to demonstrate efficacy, including effects on inflammation by
magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis
for up to 1 year with a primary focus at Week 24, in patients with active Psoriatic Arthritis
and axial Spondyloarthritis despite current or previous non-steroidal anti-inflammatory drugs
(NSAID) and/or disease modifying anti-rheumatic drug (DMARD) and/or anti-TNFα therapy.